Publications by authors named "F Giovannenze"
Background: Aetiological diagnosis and targeted antibiotic therapy are essential to improve the prognosis of patients with infective endocarditis. Molecular tests on blood have been reported to be effective in identifying the causative organism and are recommended when blood cultures are negative. The role of molecular tests on the surgically excised valve is still unclear and needs further investigation.
View Article and Find Full Text PDFIntroduction: Dalbavancin is an antibiotic characterized by an extended half-life and efficacy against methicillin-resistant Staphylococci. Currently, there are only narrative reviews summarizing the evidence about the use of dalbavancin for infective endocarditis (IE), many of which are focused primarily on its use as consolidation therapy. For this reason, we conducted a systematic review to describe the clinical efficacy and the safety of dalbavancin in IE treatment.
View Article and Find Full Text PDFImpact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: a multicentre retrospective cohort study.
J Antimicrob Chemother
November 2024
Article Synopsis
- The study investigates the impact of adequate empirical combination therapy (AECT) on 30-day mortality rates in septic shock patients infected with Pseudomonas aeruginosa.
- Of 98 patients analyzed, those receiving AECT had a significantly lower mortality rate (25%) compared to those on adequate empirical monotherapy (AEMT) (56.8%), indicating AECT may enhance survival.
- The findings suggest transitioning to a single effective antibiotic after confirming susceptibility is safe, highlighting the need for further research to validate these results.
Background: Cefiderocol is a novel β-lactam with activity against carbapenem-resistant (CRAB), but its role in CRAB pulmonary infections is controversial due to limited evidence.
Objectives: To assess the association between cefiderocol-containing regimens treatment and 28-day mortality in carbapenem-resistant ventilator-associated pneumonia (VAP).
Methods: An observational cohort study including critically ill COVID-19 patients with CRAB-VAP admitted to two ICUs of a large academic hospital in Rome between September 2020 and December 2022.